On the other hand, treatment of FXR agonist GW4064 in a type 2 diabetic kidney animal model ameliorated albuminuria, pro-fibrotic and pro-inflammatory changes, improved renal lipid metabolism and inhibited renal autophagy, apoptosis and ROS production, suggesting that FXR may also be a therapeutic target for CKD [127,128]. Here, NR1H4 is linked to chronic kidney disease.